Decision: Favourable
Study Title:
A phase III, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the safety and efficacy of AMX0035 versus placebo for 48-week treatment of adult patients with Amyotrophic Lateral Sclerosis (ALS)
NREC Code:
21-NREC-CT-022
Decision:
Favourable
Meeting Date:
21/07/2021
Study Type:
CT application
Principal Investigator:
Prof Orla Hardiman
PI Institution:
Beaumont Hospital
Sponsor:
Amylyx Pharmaceuticals